CAR T and Other Options for Relapsed/Refractory Follicular Lymphoma: Javier L. Munoz, MD, MS, FACP

The FDA will determine the acceptability of the BLA within the next 60 days.

The patient was treated at the new fifth dose level and had concomitant metapneumovirus infection.

Investigators plan to present full results from the OS analysis of the phase 3 ZUMA-7 trial at an upcoming medical meeting.

The barrier is an essential part of keeping the brain safe, but it also prevents the immune system from eliminating brain cancer tumors.

Patients in the UK with r/r multiple myeloma may still be able to access the CAR-T through ongoing clinical trials, which are not impacted by the decision.

Review top news and interview highlights from the week ending March 17, 2023.